KTTAW
Pasithea Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+174.07%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -78.9%
- EBIT
- -74.2%
- EPS
- +74.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +727.6%
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -48.5%
- EBIT
- -46.4%
- Net income
- -46.9%
- EPS
- +77.1%
- Free cash flow
- -9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026